Sector: Healthcare
findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for BIIB, sign up here.
Income Statement
Revenue
$9.8bn
Gross Profit
$7.3bn
Earning before Tax
$1.3bn
Net Income
$1.2bn
Net Income Common Shareholders
$1.2bn
EPS
8.02
Balance Sheet
Cash
$1.0bn
Debt
$7.3bn
Assets
$26.8bn
Liabilities
$12.0bn
Equity
$14.8bn
Enterprise Value
$42.9bn
Cash Flow Statement
Net Cash from Operations
$1.5bn
Net Cash from Investing
$-4.1bn
Net Cash from Financing
$149.3m
Net Cash Flow
$-2.4bn
Free Cash Flow
$1.2bn
Free Cash Flow per Share
$8.54
Metrics
Price to Equity
32.29
Price to Equity (Damodaran)
32.27
Price to Book
2.53
Net Margin
0.12
Return on Equity
0.08
Return on Sales
0.13
Get immediate access to 5-years of reference grade data for BIIB for free.
Sign upBiogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer''s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin''s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin''s lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin''s lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer''s disease and dementia, neuromuscular disorders, Parkinson''s disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Company Info
Industry
Drug Manufacturers - General
Employees
8,725
Address
225 Binney Street
Cambridge, MA 02142
United States
Phone
617 679 2000
Website
Last Updated
2024-02-08
Available Data
Standardized Financial Statements
EOD Price History
Corporate Actions
Institutional Holdings
Insider Transactions
Copyright © findl 2024. All rights reserved.